Prollenium US Revenue and Competitors
Estimated Revenue & Valuation
- Prollenium US's estimated annual revenue is currently $25.4M per year.
- Prollenium US's estimated revenue per employee is $251,000
Employee Data
- Prollenium US has 101 Employees.
- Prollenium US grew their employee count by 6% last year.
Prollenium US's People
Name | Title | Email/Phone |
---|
Prollenium US Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.8M | 39 | 3% | N/A | N/A |
#2 | $15.1M | 60 | 7% | N/A | N/A |
#3 | $6M | 24 | 0% | N/A | N/A |
#4 | $24.8M | 99 | -12% | N/A | N/A |
#5 | $19.3M | 77 | 8% | N/A | N/A |
#6 | $28.1M | 112 | 20% | N/A | N/A |
#7 | $3.8M | 15 | -46% | N/A | N/A |
#8 | $19.3M | 77 | 4% | N/A | N/A |
#9 | $45.4M | 181 | 4% | N/A | N/A |
#10 | $6.8M | 27 | N/A | N/A | N/A |
What Is Prollenium US?
Prollenium US, Inc. was founded in 2016. We are dedicated to the commercialization of aesthetic, medical products in the pharmaceutical and medical device industry. The company is committed to providing innovative products worldwide, that are safe and viable. Flagship product lines include Revanesse® Versa?, a Hyaluronic Acid Dermal Filler.
keywords:N/AN/A
Total Funding
101
Number of Employees
$25.4M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Prollenium US News
2022-04-20 - Facial Aesthetics Market Size 2022-2029| Key Players ...
Facial Aesthetics Market Size 2022-2029| Key Players Allergan, Prollenium Medical, Merz Aesthetics, Bausch Health. Market Size And Forecast. New Jersey, USA,-...
2022-04-20 - Facial Injectables Market Size, Scope And Outlook | Suneva ...
New Jersey, United States The study is a professional and comprehensive ... Prollenium Medical Technologies Inc., Sinclair Pharma.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $22.2M | 101 | 7% | N/A |
#2 | $7.5M | 102 | 34% | N/A |
#3 | $27.5M | 102 | 1% | N/A |
#4 | $25.8M | 103 | N/A | N/A |
#5 | $27.8M | 103 | -16% | N/A |